Genentech, Inc. Announces Potential Skin Cancer Breakthrough Tested At Scottsdale Healthcare Published In New England Journal of Medicine
Wednesday, 2 Sep 2009 05:00pm EDT
Genentech, Inc. announced that a study published in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients. The article appears online at NEJM.org and will be included in the September 17, issue of New England Journal of Medicine. In a Phase I clinical trial conducted in Arizona at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, Dr. Von Hoff and colleagues at Johns Hopkins University and Karmanos Cancer Institute demonstrated that GDC-0449, a Hedgehog Pathway Inhibitor, appears to shrink tumors in locally-advanced and metastatic basal cell carcinoma (BCC) while having limited side effects including a loss of sense of taste, and a small amount of hair loss and weight loss. GDC-0449 was discovered by Genentech and was jointly validated through a series of preclinical studies performed under a collaboration agreement between Genentech and Curis, Inc. Known as the Hedgehog trial, results suggest a durable clinical benefit, defined as tumor shrinkage visible on X-ray or other physical exam or improvement in symptoms without tumor growth, was observed in 18 of 33 patients evaluated.
ATTENZIONE AFTER A +30
OGGI POTREBBE VOLARE